Abstract
Previously we reported significant associations of the human leukocyte antigen (HLA)-DPB1 05:01 with memory against hepatitis B (HB) vaccination. However, the effects of HLA-DPB1 on antibodies to hepatitis B surface antigen (anti-HBs) kinetics were not explored. We followed up a cohort of 1974 HB booster recipients and quantified their 1-month and 1-year post-booster anti-HBs titers. A total of 681 subjects were randomly selected and typed for HLA-DPB1. We found that male subjects, undetectable pre-booster titers, and 05:01 homozygotes led to significantly lower post-booster anti-HBs titers. The geometric means (95% confidence interval (CI)) of 1-month post-booster anti-HBs titers were 4.68 (2.69–8.12), 23.01 (14.96–35.40) and 50.06 (27.20–92.13) mIU ml−1 for subjects carrying two, one and no HLA-DPB1 05:01 allele. The corresponding figures for 1-year post-booster anti-HBs titers were 1.26 (0.73–2.18), 4.72 (3.08–7.25) and 7.32 (3.75–13.56) mIU ml−1. There were significant associations of post-booster anti-HBs titers with the number of HLA-DPB1 risk and protective alleles. Among booster responders, anti-HBs decay rates were significantly reduced in subjects who had detectable pre-booster anti-HBs titers and the HLA-DPB1 05:01 allele. Our results indicated that HLA-DPB1 influences the kinetics of anti-HBs. The long-term memory against hepatitis B surface antigen (HBsAg) and the residual serum titers of anti-HBs after HB vaccination may be influenced by different mechanisms as evidenced by their inverse trend of associations with the 05:01 allele.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
El-Serag HB . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264–1273 e1.
Liang TJ . Hepatitis B: the virus and disease. Hepatology 2009; 49: S13–S21.
Fattovich G, Bortolotti F, Donato F . Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. JHepatol 2008; 48: 335–352.
Ganem D, Prince AM . Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118–1129.
McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142: 333–341.
Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257: 2597–2603.
Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906–908.
Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL . Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30: 1312–1317.
Lu SN, Chen CH, Chen TM, Lee PL, Wang JH, Tung HD et al. Hepatitis B virus infection in adolescents in a rural township-15 years subsequent to mass hepatitis B vaccination in Taiwan. Vaccine 2006; 24: 759–765.
Jan CF, Huang KC, Chien YC, Greydanus DE, Davies HD, Chiu TY et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51: 1547–1554.
Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40: 1415–1420.
Wu TW, Lin HH, Wang LY . Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology 2013; 57: 37–45.
Varla-Leftherioti M, Papanicolaou M, Spyropoulou M, Vallindra H, Tsiroyianni P, Tassopoulos N et al. HLA-associated non-responsiveness to hepatitis B vaccine. Tissue Antigens 1990; 35: 60–63.
Desombere I, Willems A, Leroux-Roels G . Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51: 593–604.
Hatae K, Kimura A, Okubo R, Watanabe H, Erlich HA, Ueda K et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 1992; 22: 1899–1905.
Martinetti M, De Silvestri A, Belloni C, Pasi A, Tinelli C, Pistorio A et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000; 97: 234–240.
McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA . Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997; 50: 8–14.
Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, Chen DS et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 1993; 11: 1437–1440.
Lin HH, Liao HW, Lin SK, Wang LY . HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Vaccine 2008; 26: 3414–3420.
Wu TW, Chu CC, Ho TY, Chang Liao HW, Lin SK, Lin M et al. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Hum Genet 2013; 132: 1131–1139.
Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591–595.
Guo X, Zhang Y, Li J, Ma J, Wei Z, Tan W et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011; 53: 422–428.
Li J, Yang D, He Y, Wang M, Wen Z, Liu L et al. Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study. PLoS One 2011; 6: e24221.
Wang L, Wu XP, Zhang W, Zhu DH, Wang Y, Li YP et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One 2011; 6: e17608.
Doherty PC, Zinkernagel RM . A biological role for the major histocompatibility antigens. Lancet 1975; 1: 1406–1409.
Thursz MR, Thomas HC, Greenwood BM, Hill AV . Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat genet 1997; 17: 11–12.
Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 1748–1752.
Hraber P, Kuiken C, Yusim K . Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 2007; 46: 1713–1721.
Bertoletti A, Tan AT, Gehring AJ . HBV-Specific Adaptive Immunity. Viruses 2009; 1: 91–103.
Chisari FV . Cytotoxic T cells and viral hepatitis. J ClinInvest 1997; 99: 1472–1477.
Guidotti LG, Chisari FV . To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478–483.
Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R . Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 1978; 2: 1056–1058.
Rehermann B, Nascimbeni M . Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215–229.
Amanna IJ, Slifka MK . Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 2011; 411: 206–215.
Whitacre CC, Reingold SC, O'Looney PA . A gender gap in autoimmunity. Science 1999; 283: 1277–1278.
Giron-Gonzalez JA, Moral FJ, Elvira J, Garcia-Gil D, Guerrero F, Gavilan I et al. Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 2000; 143: 31–36.
McMurray RW, Ndebele K, Hardy KJ, Jenkins JK . 17-beta-estradiol suppresses IL-2 and IL-2 receptor. Cytokine 2001; 14: 324–333.
Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH . High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 2013; 58: 262–264.
Medina KL, Strasser A, Kincade PW . Estrogen influences the differentiation, proliferation and survival of early B-lineage precursors. Blood 2000; 95: 2059–2067.
Maret A, Coudert JD, Garidou L, Foucras G, Gourdy P, Krust A et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003; 33: 512–521.
Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B . Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109: 1625–1633.
Kanda N, Tamaki K . Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999; 103: 282–288.
Palaszynski KM, Smith DL, Kamrava S, Burgoyne PS, Arnold AP, Voskuhl RR . A yin-yang effect between sex chromosome complement and sex hormones on the immune response. Endocrinology 2005; 146: 3280–3285.
Smith-Bouvier DL, Divekar AA, Sasidhar M, Du S, Tiwari-Woodruff SK, King JK et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008; 205: 1099–1108.
Amanna IJ, Carlson NE, Slifka MK . Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903–1915.
Leyendeckers H, Odendahl M, Lohndorf A, Irsch J, Spangfort M, Miltenyi S et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 1999; 29: 1406–1417.
Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146–2154.
Chu VT, Beller A, Nguyen TT, Steinhauser G, Berek C . The long-term survival of plasma cells. Scand J Immunol 2011; 73: 508–511.
Manz RA, Radbruch A . Plasma cells for a lifetime? Eur J Immunol 2002; 32: 923–927.
O'Connor BP, Cascalho M, Noelle RJ . Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med 2002; 195: 737–745.
Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755–2764.
Ellyard JI, Avery DT, Mackay CR, Tangye SG . Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen: potential roles of CXCL12, IL-6 and CD54. Eur J Immunol 2005; 35: 699–708.
Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105: 3965–3971.
van der Zwan A, Rozemuller E, Tilanus M . Sequencing based typing for HLA-DPB1: strategy for ABI equipment.. IHWG Press: Seattle, WA, USA, 2006.
Versluis LF, Rozemuller EH, Duran K, Tilanus MG . Ambiguous DPB1 allele combinations resolved by direct sequencing of selectively amplified alleles. Tissue antigens 1995; 46: 345–349.
Acknowledgements
We thank the staff of senior high schools and health stations in Hualien County and the Center of Disease Control, the Department of Health, Taiwan, for their valuable contribution. This research was supported by grants from the Mackay Medical College (981B03 & 991A01) and the National Science Council, Taiwan (NSC97-2314-B-715-001-MY3). The funding agencies played no role in the work.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Genes and Immunity website
Supplementary information
Rights and permissions
About this article
Cite this article
Wu, TW., Chu, CC., Chang Liao, HW. et al. HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy. Genes Immun 15, 47–53 (2014). https://doi.org/10.1038/gene.2013.62
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2013.62